Seasonal Affective Disorder Therapeutics Market Opportunities in 2019: Allergan Plc., Eli Lily Company, GlaxoSmithKline Plc, Pfizer Inc., Teva Pharmaceuticals Inc. and Forecast to 2028
The seasonal affective disorder (SAD) therapeutics market is pegged at around US$ 450 million in 2019, with a modest Y-o-Y increase of 3.9% over 2018, according to a recent intelligence report by Future Market Insights. While drugs and devices collectively contribute to the consumption volume of seasonal affective disorder therapeutics, the latter will remain a major shareholder in the market. Towards the end of 2019, more than 3.4 million devices are likely to be sold globally, in seasonal affective disorder...
View full press release